MedTrace Logo

The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563)

NCT00292877 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-01-24

No results posted yet for this study

Summary

The purpose of this study is to determine if treatment with anti-IL-5 antibody has a prednisone-sparing effect in patients with symptomatic eosinophilic bronchitis (with or without asthma).

Conditions

Interventions

DRUG

SB-240563 (Mepolizumab)

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • St. Joseph's Healthcare Hamilton

    lead OTHER

Principal Investigators

  • Frederick E Hargreave, MD · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2008-06-30
Completion
2008-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00292877 on ClinicalTrials.gov